Skip to main content

Table 3 Performance of models with SDF-1 to predict clinical outcomes among ischemic stroke patients with different diabetes status

From: Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial

  

Ischemic stroke patients with diabetes

  

Ischemic stroke patients without diabetes

 
 

NRI (category)

IDI

Calibration

NRI (category)

IDI

Calibration

 

Estimate

(95% CI), %

P Value

Estimate

(95% CI), %

P Value

χ2

P Value

Estimate

(95% CI), %

P Value

Estimate

(95% CI), %

P Value

χ2

P Value

Recurrent Stroke at 1 year

           

Conventional model

Reference

 

Reference

 

10.57

0.23

Reference

 

Reference

 

7.14

0.52

Conventional model + SDF-1

51.77 (17.02–86.52)

0.006

1.74 (0.53–2.94)

0.005

7.51

0.48

5.20 (-13.09-23.50)

0.58

0.005 (-0.02-0.03)

0.75

7.96

0.44

Cardiovascular events at 1 year

           

Conventional model

Reference

 

Reference

 

3.00

0.93

Reference

 

Reference

 

4.14

0.84

Conventional model + SDF-1

42.29 (11.73–72.84)

0.008

1.39 (0.31–2.46)

0.01

4.07

0.85

8.78 (-7.45-25.02)

0.29

0.14 (0.00-0.27)

0.05

8.71

0.37

All-cause mortality at 1 year

            

Conventional model

Reference

 

Reference

 

18.82

0.02

Reference

 

Reference

 

9.26

0.32

Conventional model + SDF-1

33.03 (1.26–64.80)

0.04

0.69 (-0.78-2.16)

0.36

13.22

0.10

6.46 (-9.31-22.24)

0.42

0.05 (-0.11-0.21)

0.51

8.27

0.41

  1. Abbreviations: SDF-1, stromal cell-derived factor-1; CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification index
  2. The conventional model included age, sex, current smoking, alcohol consumption, estimated glomerular filtration rate, baseline NIHSS score, medical history (hypertension, hyperlipidemia), ischemic stroke subtype, and randomized treatment